Sanofi - American Depositary Shares (SNY)

The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in pharmaceutical market is set to explode, reaching an astounding valuation of over $65 billion by 2033. This represents not merely a significant market expansion but a fundamental shift [...]

Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into high-growth sectors,

The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This notable drop came on the heels of the company's announcement and pricing of a substantial public stock offering, a move that

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Sanofi reports show significant improvements in hidradenitis suppurativa symptoms, with higher response rates and reduced lesions.

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

The company is working on a treatment for an autoimmune disease that affects the muscles.

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.

Can anything beat out Dupixent's "compelling bar" for effectiveness?